Virus-induced volatile organic compounds are detectable in exhaled breath during pulmonary infection.
File(s)Fig 4 R2.jpg (916.66 KB) Figure 5.jpg (95.16 KB)
Supporting information
Supporting information
Author(s)
Type
Journal Article
Abstract
BACKGROUND: Chronic obstructive pulmonary disease (COPD) is a condition punctuated by acute exacerbations commonly triggered by viral and/or bacterial infection. Early identification of exacerbation trigger is important to guide appropriate therapy but currently available tests are slow and imprecise. Volatile organic compounds (VOCs) can be detected in exhaled breath and have the potential to be rapid tissue-specific biomarkers of infection aetiology. METHODS: We used serial sampling within in vitro and in vivo studies to elucidate the dynamic changes that occur in VOC production during acute respiratory viral infection. Highly sensitive gas-chromatography mass spectrometry (GC-MS) techniques were used to measure VOC production from infected airway epithelial cell cultures and in exhaled breath samples of healthy subjects experimentally challenged with rhinovirus A16 and COPD subjects with naturally-occurring exacerbations. RESULTS: We identified a novel VOC signature comprising of decane and other related long chain alkane compounds that is induced during rhinovirus infection of cultured airway epithelial cells and is also increased in the exhaled breath of healthy subjects experimentally challenged with rhinovirus and of COPD patients during naturally-occurring viral exacerbations. These compounds correlated with magnitude of anti-viral immune responses, virus burden and exacerbation severity but were not induced by bacterial infection, suggesting they represent a specific virus-inducible signature. CONCLUSION: Our study highlights the potential for measurement of exhaled breath VOCs as rapid, non-invasive biomarkers of viral infection. Further studies are needed to determine whether measurement of these signatures could be used to guide more targeted therapy with antibiotic/antiviral agents for COPD exacerbations.
Date Issued
2021-07-28
Date Acceptance
2021-07-27
Citation
American Journal of Respiratory and Critical Care Medicine, 2021, 204 (9), pp.1075-1085
ISSN
1073-449X
Publisher
American Thoracic Society
Start Page
1075
End Page
1085
Journal / Book Title
American Journal of Respiratory and Critical Care Medicine
Volume
204
Issue
9
Copyright Statement
© 2021 by the American Thoracic Society
Sponsor
Wellcome Trust
Medical Research Council (MRC)
Identifier
https://www.ncbi.nlm.nih.gov/pubmed/34319857
Grant Number
215275/Z/19/Z
MR/V000098/1
Subjects
COPD
Virus infection
Volatile organic compound
Publication Status
Published
Coverage Spatial
United States
Date Publish Online
2021-07-28